Document Detail


Comparison of Whole versus Partial Vertebral Body Stereotactic Body Radiation Therapy for Spinal Metastases.
MedLine Citation:
PMID:  22335404     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The purpose of this study is to evaluate the difference in clinical outcomes for patients with metastatic spine disease treated with a whole versus partial vertebral body contouring approach. A retrospective study was performed for the clinical outcomes of 154 metastatic lesions to the spine in 117 patients treated with stereotactic body radiation therapy (SBRT) using the Cyberknife(TM) Robotic Radiosurgery System. Each patient was treated with a single session of radiotherapy using either a whole (WB) or a partial vertebral body contour approach (PB). The primary endpoint was re-treatment rate and the secondary endpoints were pain status, neurologic status, toxicity, tumor control, and survival. The WB group had a lower re-treatment rate (11% (WB) vs. 18.6% (PB), p = 0.285). Prior surgery status (β = 1.953, OR = 7.052, p <0.001) was correlated to the re-treatment rate. Trends for local tumor control were distinct for both treatment groups (X(2) 5 3.380, p-value 5 0.066). Treatment group (β = -1.1017, OR = 0.362, p = 0.029) was significantly correlated to the local tumor control rate. The 2-year survival was 25.7% in WB and 20.9% in PB (p = 0.741). Contouring the whole vertebral body for stereotactic body radiation therapy treatment of metastatic spinal lesions shows potential benefits by reducing the risk of recurrence, improving symptomatic relief and providing improved local tumor control.
Authors:
V B Patel; R E Wegner; D E Heron; J C Flickinger; P Gerszten; S A Burton
Related Documents :
15139074 - Is it possible to restore function with two percent surviving neural tissue?
22338014 - Phase i study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo...
22664824 - Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
8339214 - Limb-preserving treatment for soft tissue sarcomas of the extremities. the significance...
14635074 - Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients wit...
23525694 - A multicenter phase ii study of s-1 for gemcitabine-refractory biliary tract cancer.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Technology in cancer research & treatment     Volume:  11     ISSN:  1533-0338     ISO Abbreviation:  Technol. Cancer Res. Treat.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-02-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140941     Medline TA:  Technol Cancer Res Treat     Country:  United States    
Other Details:
Languages:  eng     Pagination:  105-15     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, University of Pittsburgh Cancer Institute. Herond2@upmc.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diastereoselective Rhodium-Catalyzed Ene-Cycloisomerization Reactions of Alkenylidenecyclopropanes: ...
Next Document:  Prospective study of the short-term adverse effects of gamma knife radiosurgery.